Tolnaftate
Other Antifungals For Topical Use
Sold as Tinactin · Tolnafate · Mycozyl AL · Mycozyl HC · Toe Fungus
- Drug class
- Other Antifungals For Topical Use
- Availability
- Prescription and OTC
- Routes
- Topical
- Markets covered
- 3
- Products on record
- 55
- FDA reports (12 mo)
- 59
Overview
Plain-language summary, compiled from the cited regulatory records
Tolnaftate is an antifungal medication [1]. It belongs to the drug class of other topical antifungals [1]. Tolnaftate is approved to cure most cases of athlete's foot (tinea pedis), ringworm (tinea corporis), and jock itch (tinea cruris) [1]. It can also help prevent the recurrence of athlete's foot and relieve associated symptoms such as itching, burning, cracking, and chafing [1].
This active ingredient is available under various brand names, including Tinactin and Formula 3 [1]. In the past 12 months, there have been 59 adverse event reports associated with tolnaftate [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 35 | May 27, 2026 |
| GB United Kingdom | MHRA | 3 | February 20, 2026 |
| CA Canada | Health Canada | 17 | April 1, 2026 |
USUnited States· FDA
35 products
Uses
Uses cures most athlete's foot (tinea pedis), ringworm (tinea corporis) and jock itch (tinea cruris) can prevent recurrence of most athlete's foot relieves symptoms of athlete's foot, including itching, burning, crcaking, and chafing associated with jock itch
How to take
GBUnited Kingdom· MHRA
3 products
Uses
For the treatment and prevention of athlete’s foot.
How to take
CACanada· Health Canada
17 products
17 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Sources & citations
- [1]FDA DailyMed · 0370c9fa-b986-3a… · revised October 30, 2025 [PDF]
- [2]MHRA (UK) · PL000890012 · revised February 20, 2026
- [3]Health Canada (DPD) · 00576034 · revised March 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.